Sumitomo Pharma Co (TSE:4506) Cyclically Adjusted Revenue per Share: 円1,278.65 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4506 Sumitomo Pharma Co Ltd TSE:4506
64 GF Score
Price 円1,270.50
GF Value 円845.98
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Sumitomo Pharma Co Cyclically Adjusted Revenue per Share?

Sumitomo Pharma Co TSE:4506 +1.80% 64 Cyclically Adjusted Revenue per Share is 円1,278.65 as of Mar. 2026. GuruFocus rates TSE:4506 with a GF Score™ of 64/100 and a GF Value™ of 円845.98 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sumitomo Pharma Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円265.675. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円1,278.65 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Sumitomo Pharma Co's average Cyclically Adjusted Revenue Growth Rate was 1.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sumitomo Pharma Co was 5.10% per year. The lowest was 1.60% per year. And the median was 4.15% per year.

As of today (2026-08-04), Sumitomo Pharma Co's current stock price is 円1270.50. Sumitomo Pharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円1,278.65. Sumitomo Pharma Co's Cyclically Adjusted PS Ratio of today is 0.99.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sumitomo Pharma Co was 3.84. The lowest was 0.25. And the median was 1.32.


Sumitomo Pharma Co  (TSE:4506) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sumitomo Pharma Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1270.50/1278.65
=0.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sumitomo Pharma Co was 3.84. The lowest was 0.25. And the median was 1.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sumitomo Pharma Co Cyclically Adjusted Revenue per Share Related Terms


Sumitomo Pharma Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Sumitomo Pharma Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co Cyclically Adjusted Revenue per Share Chart

Sumitomo Pharma Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,137.85 1,219.54 1,222.33 1,262.46 1,278.65

Sumitomo Pharma Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,268.43 1,272.97 1,284.08 1,278.65 0.00

TSE:4506 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Cyclically Adjusted PS Ratio falls into.


TSE:4506
64GF Score
Sumitomo Pharma Co Ltd TSE:4506
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sumitomo Pharma Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sumitomo Pharma Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=265.675/112.7000*112.7000
=265.675

Current CPI (Mar. 2026) = 112.7000.

Sumitomo Pharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 260.493 98.100 299.262
201609 238.114 98.000 273.831
201612 270.354 98.400 309.643
201703 258.867 98.100 297.394
201706 292.392 98.500 334.544
201709 289.918 98.800 330.706
201712 311.615 99.400 353.310
201803 281.106 99.200 319.361
201806 291.749 99.200 331.453
201809 277.485 99.900 313.039
201812 303.844 99.700 343.463
201903 282.902 99.700 319.790
201906 295.709 99.800 333.932
201909 284.723 100.100 320.562
201912 318.187 100.500 356.813
202003 316.427 100.300 355.547
202006 336.921 99.900 380.090
202009 321.276 99.900 362.440
202012 335.429 99.300 380.693
202103 305.039 99.900 344.123
202106 330.225 99.500 374.034
202109 409.104 100.100 460.600
202112 348.212 100.100 392.043
202203 322.087 101.100 359.043
202206 402.414 101.800 445.502
202209 401.249 103.100 438.611
202212 354.842 104.100 384.157
202303 239.820 104.400 258.886
202306 190.505 105.200 204.087
202309 193.702 106.200 205.558
202312 207.369 106.800 218.825
202403 200.181 107.200 210.451
202406 228.210 108.200 237.701
202409 226.721 108.900 234.632
202412 283.006 110.700 288.119
202503 265.924 111.100 269.754
202506 271.884 111.700 274.318
202509 299.831 112.000 301.705
202512 303.619 113.000 302.813
202603 265.675 112.700 265.675

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円1,278.65 mean?
Sumitomo Pharma Co (TSE:4506) has a Cyclically Adjusted Revenue per Share of 円1,278.65 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sumitomo Pharma Co and its competitors.
Is Sumitomo Pharma Co's Cyclically Adjusted Revenue per Share too high?
Sumitomo Pharma Co's current Cyclically Adjusted Revenue per Share is 円1,278.65. Overall, Sumitomo Pharma Co has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Sumitomo Pharma Co's Cyclically Adjusted Revenue per Share of 円1,278.65 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sumitomo Pharma Co and its competitors. Sumitomo Pharma Co's current Cyclically Adjusted Revenue per Share is 円1,278.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (TSE:4506) is currently considered Significantly Overvalued. The stock's GF Value™ is 円845.98, compared to a current price of 円1,270.50 — trading 50.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円1,278.65. Sumitomo Pharma Co's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Sumitomo Pharma Co (TSE:4506), the current Cyclically Adjusted Revenue per Share is 円1,278.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sumitomo Pharma Co (TSE:4506) Overvalued in 2026?

Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued. The current stock price of 円1,270.50 is trading 50.2% above its estimated GF Value™ of 円845.98. GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.

Key valuation signals for TSE:4506:

  • Cyclically Adjusted Revenue per Share: 円1,278.65
  • GF Value™: 円845.98 vs. price of 円1,270.50 (50.2% above fair value)
  • GF Score™: 64/100 with 7 warning signs

No single metric tells the full story. See the TSE:4506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sumitomo Pharma Co Business Description

Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
64GF Score

Get the complete analysis for TSE:4506

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,270.50
Price
円845.98
GF Value